Cited by 32Liver Disease Diagnosis and TreatmentLiver Diseases and ImmunityLiver Disease and Transplantation

The DOI matches its Crossref record.

The Liver Meeting: Boston, Massachusetts Nov 10-14, 2023

Massimiliano Cadamuro, Haxhiaj, L, Montanaro, C, Villa, E, Floreani, A, Nora Cazzagon, Baggio, G, Strazzabosco, M, Paolo Simioni, Fabris, L·2023·Hepatology

Abstract

Background: There is a lack of knowledge on the burden of invasive fungal disease in patients with severe alcoholic hepatitis. Methods: Among the 1,438,049 patients diagnosed with alcohol use disorders in French hospitals between 2012 and 2021, we selected individual’s with hepatic failure, portal hypertension bleeding, transjugular liver biopsy, or extrahepatic organ failure within 4 weeks following the diagnosis of alcoholic hepatitis. Our primary objective was to investigate the incidence of invasive fungal disease abd to assess the associated risk factors. We examined the 6-month mortality rate as an outcome measure. The main exposure was invasive fungal disease, while bacterial pneumonia served as the control exposure. To assess the strength of the associations, we employed multivariate logistic regression models and Cox proportional hazards models stratified by age categories, severe comorbidities, and deprivation. Results: The sample comprised 30,361 patients. Median (interquartile range) age was 55.0 (47.0-62.0) years and 73% were men. Invasive fungal disease [invasive candidosis (n=269, 0.9%); aspergillosis (n=105, 0.3%); pneumocystosis (n=47, 0.2%); cryptococcosis (n=3, 0.01%)] and bacterial pneumonia were diagnosed in 411 (1.4%) and 8,787 (10.8%) of patients, respectively. Approximately one-fifth (19.7%) of patients were documented with sepsis, and one-fourth progressed to extrahepatic organ failure. The 6-month mortality rate was ~1/4 (26.5%). Multivariate associations comprised younger ages [aOR 0.73 per decade, 95% CI (0.66-0.81) P<0.001]; sepsis [aOR 3.32, (2.63-4.21) P<0.001]; bacterial pneumonia [aOR 3.09 (2.48-3.85) P<0.001]; extrahepatic organ failure [aOR 2.19 (1.72-2.80) P<0.001]; severe comorbidities [aOR 1.14 (1.00-1.30) P<0.001]; and 6-month mortality [aOR 2.98 (2.40-3.71) P<0.001]. The probabilities of 6-month survival (95% CI) were 72.2 (71.7-72.7) and 40.5 (35.9-45.9) percent without and with invasive fungal disease, respectively (P<0.001), and 73.3 (72.8-73.9) and 63.2 (61.7-64.6) percent without and with bacterial pneumonia, respectively (P<0.001). Invasive fungal disease was associated with an independent, increased, instant, risk of 6-month death of ~80% [aHR 1.81 95% CI (1.58-2.08), P<0.001]. Bacterial pneumonia was not associated with mortality. Conclusion: Invasive fungal disease, and not bacterial pneumonia, increased the risk of 6-month mortality in patients with severe alcoholic hepatitis in France 2012-2021.

Overview

Integrity signals

Registry

Crossref · 10.1097/hep.0000000000000580

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

Sorted by citations

See all 32

Metadata

Authors
Cadamuro, M., Haxhiaj, L., Montanaro, C., Villa, E., Floreani, A., Cazzagon, N., Baggio, G., Strazzabosco, M., Simioni, P., & Fabris, L.
Affiliations
  • Université Paris Cité (FR)
  • Hôpital Cochin (FR)
  • Inserm (FR)
  • Hôpital Saint-Louis (FR)
Venue
Hepatology
Published
2023-10
Volume
78
Issue
S1
Pages
S1-S2154
ISSN
0270-9139 (ISSN-L)
OpenAlex
W4387517212
Cited by
32
References
0
Citations by year
2026: 2 · 2025: 6 · 2024: 24
FWCI
6.39
Type
journal article
Language
en
Open access
closed
Locations
  • Hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
Funders
National Institute for Health and Care Research (ACF-2022-13-004)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
liver disease
MeSH terms
Boston, Liver, Massachusetts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Liver Meeting: Boston, Massachusetts Nov 10-14, 2023. https://app.cochat.ai/papers/10.1097/hep.0000000000000580
The paper
Cadamuro, M., Haxhiaj, L., Montanaro, C., Villa, E., Floreani, A., Cazzagon, N., Baggio, G., Strazzabosco, M., Simioni, P., & Fabris, L. (2023). The Liver Meeting: Boston, Massachusetts Nov 10-14, 2023. Hepatology. https://doi.org/10.1097/hep.0000000000000580